Semax and BDNF Pathway Activity in Preclinical Neuroscience
What is Semax?
Semax is a lab-made peptide — a short chain of amino acids, the building blocks of proteins. It is made of seven of them (a heptapeptide, “hepta” meaning seven), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a neuropeptide (a peptide that acts on nerve cells) and is copied from a small piece of a natural hormone called ACTH. In lab and animal studies, researchers have looked at how it relates to BDNF (brain-derived neurotrophic factor, a protein that helps brain cells grow and survive) and to protecting nerve cells. These are research observations only, not therapeutic effects. It is supplied strictly as a research reagent for in vitro (test-tube / lab work only) use, not for human or veterinary use.
Semax takes the active piece of ACTH (called the ACTH(4–7) fragment) and adds a Pro-Gly-Pro tail. That tail slows down how fast the body’s enzymes break it apart, so Semax lasts much longer than the plain fragment. Here is the useful part: this piece of ACTH still sends nerve-related signals, but without the part of the full hormone that triggers stress hormones. That makes it a clean research tool — scientists can study these nerve signals on their own, away from the body’s stress-hormone system.
Semax comes from a long line of Eastern European research and was studied there over many decades. In the lab it is used as a neuropeptide research tool, mainly to study how short peptides change brain-growth proteins, nerve-protecting gene activity, and learning in cell cultures and rodents.
BDNF, NGF and neuroprotection
Semax research focuses on three linked areas: how it affects brain-growth proteins, how it behaves when nerve cells are damaged, and how it affects the brain chemicals tied to learning and attention.
Neurotrophic factor (BDNF/NGF) expression
The most studied thing about Semax is that it has been linked to more BDNF and NGF (nerve growth factor) in the brain. These are proteins that help nerve cells survive, grow, and form new connections (this connection-forming is called synaptic plasticity). In rodent studies, BDNF levels rose quickly in certain brain areas after Semax was given, along with changes in TrkB (the receptor that BDNF locks onto). Gene studies tracked how NGF and BDNF activity changed over time across different brain regions — and found the effect depends on the region and can go up or down, rather than being one simple uniform change.
Neuroprotection and ischaemia models
Semax has been tested in rodent models of stroke (where blood flow to part of the brain is cut off, called ischaemia) and oxidative stress (damage from harmful molecules). Researchers looked at how it relates to nerve cells surviving and to the activity of nerve-growth genes after injury. In these stroke models, Semax (and a smaller piece it breaks down into, Pro-Gly-Pro) was linked to switching on nerve-growth genes and dialling down genes tied to inflammation and cell death. This is why it is used as a research tool for studying how nerve cells can be protected. These are research observations only, not therapeutic effects.
Cognition, attention and monoamines
Beyond brain-growth proteins, studies have looked at Semax and attention, learning, and the dopamine and serotonin systems (two chemical messengers involved in mood, focus and reward). It has also been studied for how it affects enkephalins (natural pain-relieving signals). All together, this makes it a useful research tool for studying how one short peptide can affect thinking through several pathways at once.
Key research findings
The studies below are good examples of the animal-based Semax research. They are summarised here for science reference only.
Reported that intranasal Semax produced a rapid, region-specific increase in BDNF protein in the rat basal forebrain, providing direct evidence linking the peptide to neurotrophic signalling.
PMID: 16635254
Mapped the time-course of NGF and BDNF transcription across three brain regions following Semax, showing region-specific and multidirectional regulation rather than a uniform response.
PMID: 19662538
Reported that Semax and its Pro-Gly-Pro metabolite activated transcription of neurotrophins and their receptors in the cortex of rats subjected to permanent middle-cerebral-artery occlusion, supporting its neuroprotection research rationale.
Semax and Selank
Semax is often studied next to Selank, another neuropeptide made in Russia. Researchers pair them because they work on different but matching pathways — Semax on brain-growth proteins (BDNF and NGF) and Selank on the calming GABA system. Both belong to the neuropeptide research category. For a side-by-side look, see Semax vs Selank.
Velox Peptides supply information
Velox Peptides supplies Semax as a lyophilised (freeze-dried) powder at ≥99.0% HPLC-verified purity, with a batch certificate of analysis (a lab report proving what is in the vial) available on request. To work out how to reconstitute it (mix the powder back into a liquid), see the reconstitution calculator. Supplied strictly as a research reagent for in vitro use.
References & further reading
- Dolotov OV et al. “Semax, an analogue of ACTH(4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.” 2006. PMID: 16635254
- Shadrina M et al. “Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action.” 2009. PMID: 19662538
- Medvedeva EV et al. “Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.” Preclinical literature.
- Ashmarin IP et al. “Semax in the prevention of disease and the maintenance of working capacity.” Neuroscience and Behavioral Physiology, review literature.
Summaries are paraphrased from the peer-reviewed preclinical literature. For full source citations, email veloxpeps@gmail.com.
